Rhythm Pharmaceuticals (RYTM) Intangibles (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Intangibles of $5.1 million for Q1 2026, down 14.33% year-over-year from $6.0 million in Q1 2025, and down 4.0% quarter-over-quarter from $5.3 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Intangibles (2021 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Intangibles for 6 consecutive years, with $5.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 14.33% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (down 14.33% YoY), while the FY2025 annual figure was $5.3 million, down 13.85% from the prior year.
- Intangibles fell to $5.1 million in Q1 2026 per RYTM's latest filing, from $5.3 million in the prior quarter.
- Across five years, Intangibles topped out at $8.5 million in Q1 2022 and bottomed at $5.1 million in Q1 2026.
- Historically, Intangibles has averaged $6.8 million across 5 years, with a median of $6.8 million in 2024.
- Annual changes were most pronounced in 2022 — Intangibles surged 70.54% — and 2026, when it retreated 14.33%.
- Rhythm Pharmaceuticals' Intangibles stood at $7.9 million in 2022, then slipped by 10.85% to $7.0 million in 2023, then retreated by 12.15% to $6.2 million in 2024, then retreated by 13.85% to $5.3 million in 2025, then slipped by 4.0% to $5.1 million in 2026.
- Business Quant data shows RYTM's Intangibles at $5.1 million in Q1 2026, $5.3 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 4.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.89 Mn |
| Mar 31, 2026 | 5.11 Mn |
| Dec 31, 2025 | 5.32 Mn |
| Sep 30, 2025 | 5.53 Mn |
| Jun 30, 2025 | 5.75 Mn |
| Mar 31, 2025 | 5.96 Mn |
| Dec 31, 2024 | 6.17 Mn |
| Sep 30, 2024 | 6.39 Mn |
| Jun 30, 2024 | 6.60 Mn |
| Mar 31, 2024 | 6.82 Mn |
| Dec 31, 2023 | 7.03 Mn |
| Sep 30, 2023 | 7.24 Mn |
| Jun 30, 2023 | 7.46 Mn |
| Mar 31, 2023 | 7.67 Mn |
| Dec 31, 2022 | 7.88 Mn |
| Sep 30, 2022 | 8.10 Mn |
| Jun 30, 2022 | 8.31 Mn |
| Mar 31, 2022 | 8.53 Mn |
| Dec 31, 2021 | 4.66 Mn |
| Sep 30, 2021 | 4.77 Mn |